Fig. 2From: Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trialChanges in HbA1c at 4, 12, and 24Â weeks in the two treatment groupsBack to article page